Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.3K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.3K
Assembly of Signaling Complexes01:30

Assembly of Signaling Complexes

5.9K
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
5.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
The Two-State Receptor Model01:29

The Two-State Receptor Model

2.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.4K
Spare Receptors01:30

Spare Receptors

3.8K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Brain-Penetrant Nurr1 Agonist Tool.

ChemMedChem·2026
Same author

An Activator of Tailless' Repressor Function Stimulates Anti-Neurodegenerative Gene Expression.

Journal of medicinal chemistry·2026
Same author

Enhanced Intramuscular mRNA Activity of Peptide-Lipid Nanoparticles with Hydrophobized Head Groups.

Bioconjugate chemistry·2026
Same author

An Agonist/Antagonist Photo-Switchable Vitamin D Mimetic Enables Bidirectional Optical Control of VDR.

Angewandte Chemie (International ed. in English)·2026
Same author

Delivery of nano-formulated drugs to solid tumours is selectively increased by co-application of the vascular disrupting agent CA4P.

British journal of pharmacology·2026
Same author

Structural optimization of drug molecules with incrementally trained language models.

Nature communications·2026

Related Experiment Video

Updated: Sep 14, 2025

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.6K

Development of an RXR Agonist Scaffold with Pronounced Homodimer Preference.

Felix Nawa1, Arthur Kardanov1, Till Kasch1

  • 1Ludwig-Maximilians-Universität München, Department of Pharmacy, 81377 Munich, Germany.

Journal of Medicinal Chemistry
|July 24, 2025
PubMed
Summary

Researchers developed a novel retinoid X receptor (RXR) modulator. This compound selectively activates RXR homodimers, offering potential for targeted therapies by reducing promiscuous effects seen with other RXR agonists.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

12.9K

Related Experiment Videos

Last Updated: Sep 14, 2025

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.6K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

12.9K

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Drug Discovery

Background:

  • Retinoid X receptors (RXRs) are crucial in nuclear receptor signaling, involved in diverse conditions like cancer and neurodegeneration.
  • Current RXR agonists often exhibit promiscuous effects due to RXR's role in various dimeric forms.

Purpose of the Study:

  • To identify and optimize a novel RXR ligand chemotype with selective activity.
  • To investigate the potential for modulating specific RXR signaling pathways.

Main Methods:

  • Identification of a new RXR ligand chemotype.
  • Chemical optimization of the lead compound.
  • Biochemical assays to assess homodimer and heterodimer activation.
  • Co-crystal structure analysis of the RXR ligand-bound receptor.

Main Results:

  • A novel RXR modulator scaffold was developed with nanomolar potency for RXR homodimer activation.
  • The new modulator showed significantly reduced activation of RXR heterodimers compared to bexarotene.
  • Co-crystal structures revealed distinct interactions with the RXR ligand-binding domain (LBD) compared to bexarotene.

Conclusions:

  • The novel RXR modulator enables selective studies of RXR homodimer activation effects.
  • This discovery suggests that distinct molecular mechanisms of RXR activity can be therapeutically targeted.
  • This represents a significant advancement in developing more specific RXR-targeting drugs.